Drug intelligence / Profile preview

FBP001

Development stage: Preclinical
Lead developer: FasT Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

FBP001 is a monoclonal antibody developed by FasT Biopharma for the treatment of ophthalmic diseases, specifically dry age-related macular degeneration (dry AMD) and glaucoma. The therapeutic candidate is designed for intravitreal administration and functions by binding to and blocking Fas Ligand (FasL), a protein that triggers apoptotic cell death. By inhibiting FasL-mediated signaling, FBP001 aims to prevent the loss of retinal cells associated with progressive vision impairment in these conditions. As of 2024, the program is in the preclinical stage, specifically undergoing hit identification.

Targets

FASLG (Fas ligand)

Beyond the preview

Go deeper on FBP001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FBP001.

Explore the full profile